<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940705-2-00178</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 --> Section IV&hyph;C&hyph;3&hyph;e&hyph;(1). Announcements of RAC meetings and agendas at least 15  <!-- PJG 0012 frnewline --> days in advance (NOTE_If the agenda for a RAC meeting is modified, ORDA  <!-- PJG 0012 frnewline --> shall make the revised agenda available to anyone upon request at least 72 hours in  <!-- PJG 0012 frnewline --> advance of the meeting);  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;3&hyph;e&hyph;(2). Proposed Major Actions to the NIH Guidelines (see Section  <!-- PJG 0012 frnewline --> IV&hyph;C&hyph;1&hyph;b&hyph;(1)) at least 15 days prior to the RAC meeting;  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;3&hyph;f. Serve as the focal point for data management of NIH-approved  <!-- PJG 0012 frnewline --> human gene transfer protocols approved under Sections III&hyph;A&hyph;2 and III&hyph;B&hyph;2 and  <!-- PJG 0012 frnewline --> registered with NIH/ORDA as required under Section III&hyph;C&hyph;7;  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;3&hyph;g. Serve as the executive secretary of the RAC; and  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;3&hyph;h. Maintain a list of Major and Minor Actions approved under  <!-- PJG 0012 frnewline --> Section III&hyph;A&hyph;2 and III&hyph;B&hyph;3 and a list of experiments registered with NIH/ORDA as  <!-- PJG 0012 frnewline --> described in Section III&hyph;C&hyph;7.  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;4. Other NIH Components  <!-- PJG 0012 frnewline --> Other NIH components shall be responsible for certifying maximum containment  <!-- PJG 0012 frnewline --> (BL4) facilities, inspecting them periodically, and inspecting other recombinant  <!-- PJG 0012 frnewline --> DNA facilities as deemed necessary.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section IV&hyph;D. Compliance with the NIH Guidelines  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> As a condition for NIH funding of recombinant DNA research, institutions shall  <!-- PJG 0012 frnewline --> ensure that such research conducted at or sponsored by the institution, irrespective  <!-- PJG 0012 frnewline --> of the source of funding, shall comply with the NIH Guidelines. The policies on  <!-- PJG 0012 frnewline --> noncompliance are as follows:  <!-- PJG 0012 frnewline --> All NIH-funded projects involving recombinant DNA techniques must comply with  <!-- PJG 0012 frnewline --> the NIH Guidelines. Non-compliance may result in: (i) suspension, limitation, or  <!-- PJG 0012 frnewline --> termination of financial assistance for such projects and of NIH funds for other  <!-- PJG 0012 frnewline --> recombinant DNA research at the institution, or (ii) a requirement for prior NIH  <!-- PJG 0012 frnewline --> approval of any or all recombinant DNA projects at the institution.  <!-- PJG 0012 frnewline --> All non-NIH funded projects involving recombinant DNA techniques conducted at  <!-- PJG 0012 frnewline --> or sponsored by an institution that receives NIH funds for projects involving such  <!-- PJG 0012 frnewline --> techniques must comply with the NIH Guidelines. Noncompliance may result in: (i)  <!-- PJG 0012 frnewline --> suspension, limitation, or termination of NIH funds for recombinant DNA research  <!-- PJG 0012 frnewline --> at the institution, or (ii) a requirement for prior NIH approval of any or all  <!-- PJG 0012 frnewline --> recombinant DNA projects at the institution.  <!-- PJG 0012 frnewline --> Information concerning noncompliance with the NIH Guidelines may be brought  <!-- PJG 0012 frnewline --> forward by any person. It should be delivered to both NIH/ORDA and the relevant  <!-- PJG 0012 frnewline --> institution. The institution, generally through the Institutional Biosafety Committee,  <!-- PJG 0012 frnewline --> shall take appropriate action. The institution shall forward a complete report of the  <!-- PJG 0012 frnewline --> incident recommending any further action to the Office of Recombinant DNA  <!-- PJG 0012 frnewline --> Activities, National Institutes of Health, Building 31, Room 4B11, Bethesda,  <!-- PJG 0012 frnewline --> Maryland 20892, (301) 496&hyph;9838.  <!-- PJG 0012 frnewline --> In cases where NIH proposes to suspend, limit, or terminate financial assistance  <!-- PJG 0012 frnewline --> because of noncompliance with the NIH Guidelines, applicable DHHS and Public  <!-- PJG 0012 frnewline --> Health Service procedures shall govern.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section IV&hyph;E. Voluntary Compliance  <!-- PJG 0012 frnewline --> Section IV&hyph;E&hyph;1. Basic Policy  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Individuals, corporations, and institutions not otherwise covered by the NIH  <!-- PJG 0012 frnewline --> Guidelines are encouraged to do so by following the standards and procedures set  <!-- PJG 0012 frnewline --> forth in Sections I through IV. In order to simplify discussion, references hereafter  <!-- PJG 0012 frnewline --> to ``institutions'' are intended to encompass corporations and individuals who have  <!-- PJG 0012 frnewline --> no organizational affiliation. For purposes of complying with the NIH Guidelines, an  <!-- PJG 0012 frnewline --> individual intending to carry out research involving recombinant DNA is encouraged  <!-- PJG 0012 frnewline --> to affiliate with an institution that has an Institutional Biosafety Committee  <!-- PJG 0012 frnewline --> approved under the NIH Guidelines.  <!-- PJG 0012 frnewline --> Since commercial organizations have special concerns, such as protection of  <!-- PJG 0012 frnewline --> proprietary data, some modifications and explanations of the procedures are  <!-- PJG 0012 frnewline --> provided in Sections IV&hyph;E&hyph;2 through IV&hyph;E&hyph;5&hyph;b in order to address these concerns.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section IV&hyph;E&hyph;2. Institutional Biosafety Committee Approval  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> It should be emphasized that employment of an Institutional Biosafety Committee  <!-- PJG 0012 frnewline --> member solely for purposes of membership on the Institutional Biosafety Committee  <!-- PJG 0012 frnewline --> does not itself make the member an institutionally affiliated member. Except for  <!-- PJG 0012 frnewline --> the unaffiliated members, a member of an Institutional Biosafety Committee for an  <!-- PJG 0012 frnewline --> institution not otherwise covered by the NIH Guidelines may participate in the  <!-- PJG 0012 frnewline --> review and approval of a project in which the member has a direct financial interest  <!-- PJG 0012 frnewline --> so long as the member has not been, and does not expect to be, engaged in the  <!-- PJG 0012 frnewline --> project. Section IV&hyph;B&hyph;2&hyph;a&hyph;(4) is modified to that extent for purposes of these  <!-- PJG 0012 frnewline --> institutions.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            